JOURNAL OFVIROLOGY, Dec. 2007, p. 13092–13104 Vol. 81, No. 23
0022-538X/07/$08.00!0 doi:10.1128/JVI.01378-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Varicella-Zoster Virus Modulates NF-"B Recruitment on Selected
Cellular Promoters
!
Nadia El Mjiyad, Se´bastien Bontems, Geoffrey Gloire, Julie Horion, Patricia Vandevenne,
Emmanuel Dejardin, Jacques Piette, and Catherine Sadzot-Delvaux*
GIGA-Research, Virology and Immunology Unit, GIGA B34, University of Lie`ge, B-4000 Lie`ge, Belgium Received 25 June 2007/Accepted 31 August 2007
Intercellular adhesion molecule 1 (ICAM-1) expression is down-regulated in the center of cutaneous vari-cella lesions despite the expression of proinflammatory cytokines such as gamma interferon and tumor necrosis factor alpha (TNF-!). To study the molecular basis of this down-regulation, the ICAM-1 induction of TNF-! was analyzed in varicella-zoster virus (VZV)-infected melanoma cells (MeWo), leading to the following observations: (i) VZV inhibits the stimulation of icam-1 mRNA synthesis; (ii) despite VZV-induced nuclear translocation of p65, p52, and c-Rel, p50 does not translocate in response to TNF-!; (iii) the nuclear p65 present in VZV-infected cells is no longer associated with p50 and is unable to bind the proximal NF-"B site of the icam-1 promoter, despite an increased acetylation and accessibility of the promoter in response to TNF-!; and (iv) VZV induces the nuclear accumulation of the NF-"B inhibitor p100. VZV also inhibits icam-1 stimulation of TNF-! by strongly reducing NF-"B nuclear translocation in MRC5 fibroblasts. Taken together, these data show that VZV interferes with several aspects of the immune response by inhibiting NF-"B binding and the expression of target genes. Targeting NF-"B activation, which plays a central role in innate and adaptive immune responses, leads to obvious advantages for the virus, particularly in melanocytes, which are a site of viral replication in the skin.
Varicella-zoster virus (VZV) is a human alphaherpesvirus responsible for two diseases. It causes varicella (chicken pox), establishes latency in sensory ganglia, and may reactivate to cause herpes zoster (shingles) in the host (58). VZV enters the host via the respiratory mucosal epithelium, from which it is transported to the skin via a cell-associated viremia (3, 36, 38, 41). It was proposed that melanocytes are the main site of viral replication in the skin prior to the appearance of the typical vesicular lesions (23). Finally, the virus reaches the sensory ganglia, where it may remain latent for years (12, 13, 20, 50). The innate immune response to VZV seems to be charac-terized by the production of granulysin by NK cells and of alpha interferon (IFN-#), reducing viral replication (1, 24). In vitro, inflammatory cytokines were also shown to be produced, in a Toll-like receptor 2-dependent manner, by monocytes/ macrophages (57). In addition, peripheral blood mononuclear cells from patients with acute varicella infection produce larger amounts of IFN-$, tumor necrosis factor alpha (TNF-#), and interleukin-12 (IL-12) in vitro than do those from naı¨ve pa-tients, and these cytokines were also shown to be capable of inhibiting viral replication at an early time of infection (29, 54). Furthermore, these cytokines have been detected in the blood-stream of VZV-infected patients, suggesting that they have a crucial role in the control of VZV infection (for reviews, see references 1 and 54). Like many other viruses, VZV evades the immune response in different ways (2, 4, 43). A study on skin biopsies reported that VZV down-regulates intercellular
ad-hesion molecule 1 (ICAM-1; CD54) in infected cells located in the center of cutaneous vesicular lesions, despite the presence of IFN-$ and TNF-# (45), suggesting that the modulation of ICAM-1 expression in response to proinflammatory cytokines could have a major influence on viral replication in skin.
ICAM-1, an 80- to 114-kDa inducible surface glycoprotein, belongs to the immunoglobulin superfamily and is involved in a wide range of immune responses (52). ICAM-1 binds to LFA-1 and Mac-1, two integrins expressed by leukocytes. This interaction promotes cell adhesion and leukocyte extravasation (17, 52). It has also been shown that ICAM-1 expression on nonendothelial cells also plays a key role in the immune re-sponse, especially for the activation of CD8!T cells (39, 40).
The icam-1 promoter contains two putative TATA boxes, two sites for NF-"B, AP-1, AP-2, and the GC receptor element, and one IFN-$ activated site (GAS) (14, 28, 56). ICAM-1 expression can be induced by proinflammatory cytokines such as IL-1% and TNF-#, which stimulate its expression mainly via NF-"B activation (49).
NF-"B consists of two subunits of either homo- or het-erodimers of RelA (p65), RelB, c-Rel, NF-"B1 (p105 pro-cessed to p50), and NF-"B2 (p100 propro-cessed to p52) (25). Most NF-"B complexes are sequestered in the cytoplasm and prevented from activating transcription by proteins referred to as inhibitors of NF-"B or I"B proteins (I"B#, -%, and -ε, p100, and p105). After stimulation, the I"B proteins are phosphory-lated by the I"B kinases (IKKs), ubiquitinated, and degraded by the proteasome, allowing nuclear translocation of freed NF-"B (35). Two main pathways leading to NF-"B activation have been described. The classical pathway, activated by proin-flammatory cytokines such as TNF-# and IL-1%, leads to IKK complex activation, I"B# degradation, and mostly p50-p65 het-erodimer nuclear translocation. On the other hand, the
so-* Corresponding author. Mailing address: GIGA-Research, Virology and Immunology Unit, GIGA B34, University of Lie`ge, B-4000 Lie`ge, Belgium. Phone: 32-4-3663673. Fax: 32-4-3664534. E-mail: csadzot@ulg .ac.be.
!Published ahead of print on 12 September 2007.
called alternative pathway, activated by LT%, BAFF, CD40, and some viruses, leads to p100 processing into p52, which generally translocates with RelB (8, 15, 25, 30, 35). NF-"B possesses the ability to promote the expression of numerous proteins involved in innate and adaptive immunity and thus regulates the immune response following various stimuli, in-cluding infections. Several viruses, herpesviruses in particular, have developed strategies to interfere with NF-"B activation in order to evade the immune response or to activate it for their own interest (5, 6, 42). A microarray analysis of VZV-infected fibroblasts revealed that several NF-"B-dependent genes were down-regulated during VZV infection (31), and it was recently shown that VZV inhibits NF-"B translocation in infected fi-broblasts (30), but not much is known about the molecular basis of this NF-"B inhibition in VZV-infected cells.
Since a down-regulation of ICAM-1 was observed in VZV-induced skin lesions despite the presence of TNF-#, we studied the inhibition of ICAM-1 stimulation by TNF-# in VZV-infected human melanoma cells (MeWo) and human fibroblasts (MRC5). We demonstrate in this paper that this inhibition occurs at the transcriptional level, since the icam-1 mRNA was not synthesized in VZV-infected cells. We also show by electrophoretic mobility shift assay (EMSA) that the nuclear NF-"B subunits present in VZV-infected cells are unable to bind the NF-"B site on the
icam-1 promoter following TNF-# treatment. We also highlight
the observation that despite a steady-state level of p65, this sub-unit was drastically less associated with p50 in VZV-infected MeWo cells. Using coimmunoprecipitation experiments, we dem-onstrate that both p65 and p50 are more associated with p100 in VZV-infected MeWo cells. Moreover, using chromatin immuno-precipitation (ChIP) assays of MeWo cells, we highlight that the recruitment of the NF-"B subunits p50, p65, and p52 to the
icam-1 promoter upon TNF-# treatment is strongly inhibited by
infection. This inhibition occurs while both protein and mRNA levels of I"B# are already very low. The inhibition of the NF-"B pathway is specific, since the STAT-1 activation pathway was intact in VZV-infected MeWo cells. We concluded that VZV specifically inhibits the NF-"B activation pathway by destabilizing p65-p50 heterodimers and increasing their cytoplasmic associa-tion with p100.
MATERIALS AND METHODS
Cell culture and viruses.The human melanoma cell line MeWo and the fibroblast cell line MRC5 were cultured in Eagle’s minimal essential medium (Biowhitaker, Petit-Rechain, Belgium) supplemented with 10% fetal bovine se-rum, 1% glutamine, and 1% nonessential amino acids (GIBCO, Merelbeke, Belgium). We used the VZV strain rOKA-gfp, a recombinant strain expressing the gfp gene under the control of the cytomegalovirus immediate-early promoter, to infect MeWo cells and the VZV strain rOKA, which does not express green fluorescent protein (a kind gift from Marvin Sommer) (59), to infect MRC5 cells. The cells were infected by coculture with infected cells at a ratio of 1 to 10.
Protein extraction, EMSAs, and supershift experiments.Nuclear and cyto-plasmic extraction and gel shift experiments were performed as previously de-scribed (55), using either a probe carrying the proximal NF-"B sequence of the human icam-1 promoter or the "B sequence of the human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter. The supershift experiments were performed by incubating 5 &g of nuclear proteins with 2 &g of antibody for 20 min prior to reaction with a DNA probe (for p65, sc109x; for p50, sc1191x; for cRel, sc6955x; for RelB, sc226x; and for p52, sc7386x [Tebu Bio, CA]).
Western blotting.Twenty micrograms of cytoplasmic or nuclear extract was incubated with sodium dodecyl sulfate (SDS) loading buffer (10 mM Tris-HCl, pH 6.8, 1% SDS, 25% glycerol, 0.1 mM %-mercaptoethanol, and 0.03% bromo-phenol blue), boiled for 3 min, and subjected to SDS-polyacrylamide gel
elec-trophoresis. After transfer to a polyvinylidene fluoride membrane (Roche Ap-plied Sciences, Basel, Switzerland) and blocking with PBS-Tween containing 5% dry milk, the membrane was incubated at room temperature under agitation with different antibodies, including antibodies to ICAM-1, p105/p50, and p65 (Tebu Bio, CA); actin (Sigma, Bornem, Belgium); RelB, c-Rel, p100/p52, and Nijmegen breakage syndrome (NBS) (Upstate Cell Signaling, Charlottesville, VA); and I"B# (kindly provided by R. Hay, St. Andrews, Scotland).
Coimmunoprecipitation assays.Cells were lysed in 300 &l of immunoprecipi-tation buffer (25 mM HEPES, 150 mM NaCl, 0.5% Triton, 10% glycerol, 1 mM dithiothreitol, 1 mM Na3VO4, 25 mM %-glycerophosphate, 1 mM NaF,
Com-plete, 1 mM nitrophenyl phosphate). One milligram of total cell extract was incubated overnight in 1 ml of immunoprecipitation buffer with 2 &g of antibody (for p65, sc-109 [Tebu Bio, CA]; for p50, 06-886 [Upstate Cell Signaling, Char-lottesville, VA]; for p52/p100, 06-413 [Upstate Cell Signaling, CharChar-lottesville, VA]; and for hemagglutinin, 1867423 [Roche Applied Sciences, Basel, Switzer-land]). The cell lysate and the antibody were then incubated for 2 h with protein G-agarose beads (SPA-806; Stressgene). The beads were washed three times in the immunoprecipitation buffer. The beads were then incubated with 30 &l of 2% SDS for 10 min at 37°C and centrifuged at 14,000 rpm for 1 min. The eluted proteins were incubated with the SDS loading buffer, boiled for 3 min, and subjected to SDS-polyacrylamide gel electrophoresis. Western blot analysis was used to detect the coimmunoprecipitated proteins.
The same protocol was used for coimmunoprecipitation in nuclear extracts, except that 500 &g of nuclear extract was incubated in 1 ml of immunoprecipi-tation buffer.
mRNA expression studies.Total RNAs were extracted and cDNAs prepared as previously described (55). Two microliters of cDNA was subjected to quan-titative PCR using the SYBR green mix method (Applied Biosystems, War-rington, United Kingdom). The following primers were used: for icam-1, FW (5'-GCAGACAGTGACCATCTACAGCTT-3') and RV (5'-CTTCTGAGACC TCTGGCTTCGT-3'); for il-8, FW (5'-GAAGGAACCATCTCACTGTGTGT AA-3') and RV (5'-ATCAGGAAGGCTGCCAAGAG-3'); for i"b#, FW (5'-C CAACCAGCCAGAAATTGCT-3') and RV (5'-TCTCGGAGCTCAGGATCA CA-3'); and for 18S, FW (5'-AACTTTCGATGGTAGTCGCCG-3') and RV (5'-CCTTGGATGTGGTAGCCGTTT-3').
ChIP assays. ChIP assays were carried out according to the Upstate Cell Signaling protocol. Protein A-agarose beads were saturated with herring sperm DNA (Sigma-Aldrich, Bornem, Belgium) at 1 &g DNA/20 &l protein A-agarose. All ChIP assays were performed at least three times. Quantitative PCR targeting the promoter region of each gene was performed on the immunoprecipitated DNA. The following primers were designed using the software Primer Express: for icam-1, FW (5'-CCCGATTGCTTTAGCTTGGAA-3') and RV (5'-CCGG AACAAATGCTGCAGTTAT-3'); and for il-8, FW (5'-GCCATCAGTTGCAA ATCGTG-3') and RV (5'-AGTGCTCCGGTGGCTTTT-3'). As a control of binding specificity, we amplified a noncoding region downstream of the albumin gene (as previously described [37]). For specific binding to the beads, treated cell extracts were incubated with 2 &g of irrelevant antibody (anti-Flag). The follow-ing antibodies were used: antibodies to p65, p50, histone H3 acetylated at K9, histone H3 acetylated at S10, p52 (Upstate Cell Signaling, Charlottesville, VA), and histone H3 (Abcam, Cambridge, United Kingdom).
Western blot quantification.Quantification was achieved by quantifying the densities of the bands obtained by Western blotting, using the program Quantity One (Bio-Rad Laboratories Inc.).
RESULTS
ICAM-1 is not induced by TNF-! in VZV-infected cells.Since ICAM-1 was shown to be down-regulated in the center of VZV cutaneous lesions while proinflammatory cytokines were present (45), the basis of this down-regulation in VZV-infected cells was investigated. A human melanoma cell line (MeWo) infected with the VZV strain rOka labeled with green fluorescent protein, allowing follow-up of the infection, was used. At 24 and 36 h postinfection, 50 and 90% of the MeWo cells, respectively, were infected. Cells were then treated for 24 h with TNF-# (500 U/ml), a proinflammatory cytokine known to induce ICAM-1 expression, mostly via the NF-"B classical activation pathway (49). ICAM-1 expression was detected by Western blot analysis of total cell lysates. TNF-# induced ICAM-1 expression in mock-infected
cells, but the induction was strongly reduced in VZV-infected cells as early as 24 h postinfection and totally inhibited when cells were treated at 36 h postinfection (Fig. 1A). Similar results were observed using IL-1%, another proinflammatory cytokine also known to stimulate ICAM-1 expression via NF-"B activation (49) (data not shown). It can be concluded that VZV-infected cells do not respond to proinflammatory cytokine-induced ICAM-1 ex-pression, mimicking the situation described for skin lesions (45).
icam-1 gene transcription is down-regulated in
VZV-in-fected cells treated with TNF-!.Quantitative reverse transcrip-tion-PCR (RT-PCR) was used to determine whether icam-1 mRNA synthesis was induced in VZV-infected MeWo cells in response to TNF-# (18S RNA was used as an internal control). As shown in Fig. 1B, VZV reduced the basal level of icam-1 gene expression (0 h). As expected, TNF-# (500 U/ml) up-regulated icam-1 gene transcription up to sixfold as early as 3 h after treatment of mock-infected cells, while icam-1 gene tran-scription was not induced in VZV-infected cells. To ensure that these observations were not due to a destabilization of the mRNA, the stability of icam-1 mRNA was measured by treat-ing cells with a transcription inhibitor, actinomycin D (5 &g/ ml), and the transcript half-lives in mock- and VZV-infected cells were compared. The icam-1 mRNA half-lives in both mock- and VZV-infected cells were quite similar, at around 30 min (data not shown). In conclusion, VZV does not alter the mRNA stability but inhibits ICAM-1 expression in response to TNF-# by inhibiting its transcription.
Since the basal level of expression of the icam-1 gene was already lowered by the VZV infection, we could not exclude the possibility that there was a general shutoff of the cellular promoters. We then investigated whether the il-8 gene, an NF-"B-dependent gene that was not down-regulated upon in-fection, could respond to TNF-# in VZV-infected cells. il-8 gene transcription following TNF-# treatment was induced up to 180-fold after 1 hour of TNF-# treatment in mock-infected cells (Fig. 1C). Interestingly, VZV infection alone was able to regulate il-8 gene transcription up to 7-fold, and this up-regulation was further increased, up to 34-fold, in VZV-in-fected cells after TNF-# treatment (500 U/ml). Yet even if the
il-8 promoter still responded to TNF-# treatment, the
induc-tion was very weak compared to that in mock-infected cells, and it rapidly reached a plateau, meaning that there was still a limiting factor induced by VZV infection. Altogether, these data show that VZV infection is able to interfere with or even to inhibit the transcription of NF-"B-dependent genes in re-sponse to TNF-#.
In vitro, NF-"B DNA-binding ability is specifically inhibited in VZV-infected cells.The icam-1 promoter contains two pu-tative TATA boxes, two sites for NF-"B, AP-1, AP-2, and the GC receptor element, and one site for GAS (14, 28, 56). While the distal NF-"B site seems to be dispensable, the proximal
one has a major role in the response to proinflammatory cy-tokines, such as TNF-#, IL-1%, and IFN-$ (49). TNF-# and IL-1% activate NF-"B via the classical pathway, inducing the degradation of I"B# and thus releasing p50-p65 heterodimers (25). The binding of this dimer to the proximal NF-"B site within the icam-1 promoter is essential and sufficient to trigger transcription activation in response to TNF-# (56).
Nuclear NF-"B binding to the icam-1 proximal NF-"B site was investigated in mock- and VZV-infected cells by mobility shift assay. As shown in Fig. 2A (upper panel), TNF-# induced NF-"B binding to the icam-1 probe as early as 30 min in
FIG. 1. ICAM-1 is not induced by TNF-# treatment in VZV-infected cells. (A) MeWo cells infected with VZV for 24 and 36 h were treated with TNF-# (500 U/ml) for 24 h. Total cell lysates were harvested, and the level of ICAM-1 was analyzed by Western blotting. After 24 h, 50% of the MeWo cells were infected, and after 36 h, 80 to 90% of the cells were infected. The actin expression level was used as a loading control. (B) MeWo cells were mock or VZV infected for 36 h and treated for increasing times with TNF-# (500 U/ml). icam-1 mRNA expression was analyzed by quantitative RT-PCR and normalized using the 18S RNA level. (C) MeWo cells were either mock or VZV infected for 36 h before being treated with TNF-# (500 U/ml) for increasing times. Total RNA extracts were isolated and analyzed by real-time RT-PCR, using primers for the il-8 mRNA. RT-PCR was normalized using the 18S RNA expression level.
FIG. 2. NF-"B binding ability is inhibited by VZV infection. (A) MeWo cells were either mock or VZV infected for 36 h prior to treatment with TNF-# (200 U/ml) for increasing times. Nuclear ex-tracts were harvested. The nuclear exex-tracts were used to study NF-"B activation by EMSA, using a radiolabeled probe carrying the sequence of the icam-1 promoter’s proximal NF-"B site (top) or the HIV LTR promoter NF-"B sequence (bottom). (B) The NF-"B subunits in-volved in binding were characterized by supershift experiments. MeWo cells not infected by VZV were treated with TNF-#, and nuclear extraction was performed. The nuclear extracts were incubated with antibodies directed against every NF-"B subunit before starting the EMSA. n.s., nonspecific.
mock-infected MeWo cells, whereas this binding was com-pletely inhibited in VZV-infected cells. It should also be noted that the basal level of NF-"B binding on the icam-1 probe was also reduced by the infection. The binding of NF-"B to another probe, carrying the NF-"B binding sequence of the HIV LTR promoter, was also tested in order to see whether the inhibi-tion was specific to the icam-1 promoter. While VZV totally inhibited the NF-"B binding on the icam-1 probe, it less se-verely inhibited binding to the HIV probe (Fig. 2A, lower panel). Finally, a supershift experiment using antibodies di-rected against the different NF-"B subunits was carried out. As shown in Fig. 2B, p65 and p50 were the main subunits binding the icam-1 and HIV probes in response to TNF-#.
Mock- and VZV-infected cells were then treated with IFN-$ to check STAT-1 activation in order to ensure that NF-"B inhibition was specific. As shown in Fig. 3, not only was STAT-1 still phosphorylated on both Y701 and S727 (Fig. 3A), but it translocated to the nuclei of VZV-infected cells in re-sponse to IFN-$ (Fig. 3B) and was still able to bind a probe carrying the GAS sequence of the icam-1 gene (Fig. 3C). In-terestingly, binding to the GAS probe was increased upon VZV infection. These experiments clearly highlighted the VZV-specific inhibition of NF-"B activation while the cells were still able to mount a normal STAT-1 activation.
I"B! expression is reduced in VZV-infected cells at late times of infection.I"B# is the cytoplasmic inhibitor of NF-"B. Western blot analysis revealed that in mock-infected cells,
TNF-# induced a transient degradation of I"B#, while in VZV-infected MeWo cells, the basal level of I"B# protein was already very low and slightly decreased after 1 h of TNF-# treatment (Fig. 4A). The i"b# transcription level analyzed by quantitative RT-PCR revealed that mRNA synthesis was no longer induced by TNF-# in VZV-infected cells (Fig. 4B). Moreover, the basal level of expression of this gene was re-duced by VZV infection. Altogether, these data suggest that VZV infection inhibits I"B# neosynthesis.
VZV infection impairs p50 but not p65 nuclear transloca-tion.In order to determine whether the VZV-induced inhibi-tion of NF-"B binding in the presence of TNF-# was due to a cytoplasmic retention of some or all NF-"B components, the intracellular localization of the different NF-"B subunits was analyzed by Western blotting of nuclear and cytoplasmic ex-tracts. As shown in Fig. 5A (panel 1), p65 translocated into the nuclei of mock-infected cells upon TNF-# treatment. VZV by itself led to p65 translocation, as indicated by the high basal level of p65 in the nuclei of untreated infected cells (0 min). However, the amount of nuclear p65 was not increased any further by TNF-#. p50 analysis revealed its correct nuclear translocation in mock-infected cells upon TNF-# treatment, while its basal level was not increased in infected cells and was maintained low upon TNF-# induction (Fig. 5A, panel 2). From these observations, it appears that VZV infection pro-motes the nuclear translocation of p65 independently of p50. It is interesting that while the level of I"B# was already low in VZV-infected cells, p50-containing dimers still failed to trans-locate into the nucleus.
FIG. 3. The STAT-1 activation pathway is not inhibited at 36 h postinfection. (A) Mock- and VZV-infected cells were treated with IFN-$ for increasing times. STAT-1 was then immunoprecipitated from total cell lysates. The phosphorylation on Y701 and S727 was analyzed by Western blotting. A Western blot against STAT-1 was performed as a loading control. (B) Nuclear extracts were harvested from mock- and VZV-infected cells treated with IFN-$ for 30 and 60 min. Western blot analysis was carried out using an antibody directed against STAT-1. (C) MeWo cells were either mock or VZV infected for 36 h prior to treatment with IFN-$ (150 U/ml) for increasing times. Nuclear extracts were harvested and analyzed for STAT-1 activation by EMSA, using a radiolabeled probe carrying the sequence of the icam-1 promoter GAS site. n.s., nonspecific.
FIG. 4. I"B# level is lowered at late times of infection. (A) MeWo cells were either mock or VZV infected for 36 h prior to treatment with TNF-# (200 U/ml) for increasing times. The cytoplasmic extracts were harvested and used for Western blot analysis of I"B# protein expression. A Western blot of the HSP60 protein was used as a loading control. (B) MeWo cells were either mock or VZV infected for 36 h before treatment for increasing times with TNF-# (500 U/ml). Total RNA extracts were isolated and analyzed by real-time RT-PCR, using primers for i"b# mRNA. RT-PCR was normalized using the 18S RNA expression level.
The analysis of the other NF-"B subunits revealed that c-Rel nuclear translocation was observed in mock-infected cells treated with TNF-#, while VZV infection led to a basal level of c-Rel which was significantly higher than that in mock-infected cells and did not increase in response to TNF-# (Fig. 5A, panel 3). Therefore, c-Rel behaves rather similarly to p65. Neverthe-less, this study was not pursued any further since it appeared that c-Rel does not bind the icam-1 promoter upon TNF-# treatment (Fig. 2B).
Other NF-"B subunits, such as p100/p52 and RelB, were also analyzed. Interestingly, nuclear levels of both p100 and p52 were strongly increased in VZV-infected cells but were not modified by TNF-# treatment (Fig. 5B, panel 1). No clear differences in the nuclear level of RelB between mock- and VZV-infected cells, either treated or not with TNF-#, were detected (Fig. 5B, panel 2). p105, an exclusively cytoplasmic protein, and NBS, an exclusively nuclear protein, were used as quality controls (Fig. 5B, panels 3 and 4). An anti-actin West-ern blot analysis was also done to control gel loading (Fig. 5B, panel 5).
VZV destabilizes p50, reducing the occurrence of p50-asso-ciated p65.Since p65-p50 heterodimers are critical for TNF-#-induced icam-1 transcription (51), the extent to which the NF-"B subunits interact with each other was investigated by immunoprecipitation of mock- and VZV-infected cells. As shown in Fig. 6A (lanes 1 and 2), p65 was significantly less associated with p50 in VZV-infected MeWo cells than in un-infected cells. While its association with p52 was not influenced by infection, p65 seemed slightly more associated with the inhibitor p100 in VZV-infected cells. Concerning p50-contain-ing complexes (Fig. 6A, lanes 3 and 4), it seemed that the p50 remaining in the VZV-infected cells was still associated with p65 and p52, while p50 seemed slightly more associated with p100. Finally, p100 and p52 were immunoprecipitated (Fig. 6A, lanes 5 and 6). For equal amounts of these subunits, equivalent amounts of p65 and p50 were coimmunoprecipi-tated in mock- and VZV-infected cells.
Finally, p65 was immunoprecipitated from nuclear extracts of TNF-#-treated mock- and VZV-infected MeWo cells (Fig. 6B). It turned out that the nuclear p65 in VZV-infected cells
FIG. 5. Nuclear translocation of NF-"B subunits is disrupted by VZV infection of MeWo cells. MeWo cells were either mock or VZV infected for 36 h prior to treatment with TNF-# (200 U/ml) for increasing times. The nuclear and cytoplasmic levels of various NF-"B subunits, activated mostly via the classical NF-"B activation pathway (p65, p50, and c-Rel) (A) or the alternative pathway (p100, p52, and RelB) (B), were analyzed by Western blotting. Nuclear and cytoplasmic contaminations were evaluated using anti-p105 and anti-NBS antibodies, respectively. Actin was used as a loading control.
was no longer associated with a detectable amount of p50. With this dimer being the most important for icam-1 gene stimulation by TNF-# treatment (14, 49, 51), it could be envi-sioned that its destabilization by the VZV infection strongly compromised icam-1 transcription induced by TNF-#. In ad-dition, it should be mentioned that an equivalent amount of p52 was coimmunoprecipitated with p65, while p100 could not be coimmunoprecipitated with p65 from the same nuclear ex-tracts (data not shown).
VZV-infected fibroblasts also show an inhibition of NF-"B nuclear translocation. Recently, it was shown that VZV in-duced I"B# stabilization in fibroblasts at the beginning of the infection, with a cytoplasmic retention of both p65 and p50 (30). In order to compare our results to these data, experi-ments were repeated with MRC5 fibroblasts infected with the VZV strain rOka. VZV-infected MRC5 cells did not respond to TNF-# (Fig. 7A). Indeed, ICAM-1 synthesis was inhibited as early as 24 h postinfection. Band shift assays were also carried out on nuclear extracts from mock- and VZV-infected cells and clearly showed that NF-"B binding upon TNF-# treatment was as inhibited by infection in MRC5 cells as it was in MeWo cells, even though the basal level of binding was not affected by
the infection (Fig. 7B). Finally, cell fractionation was carried out, and p65, p50, p52, and p100 nuclear translocation was analyzed. As shown in Fig. 7C, p65 nuclear translocation in-creased as much in VZV-infected MRC5 cells as it did in MeWo cells. Nevertheless, the nuclear p65 level was slightly lower than that in the nuclei of TNF-#-treated mock-infected cells. We also observed a slight increase of p50 which was not observed in MeWo cells. p100 and p52 also increased in VZV-infected MRC5 nuclei. It is interesting that TNF-# induced the nuclear translocation of p52 in mock-infected MRC5 cells but not in VZV-infected cells. Thus, it turned out that despite some differences between the two cell lines considered, the virus inhibited NF-"B induction of icam-1 in both MeWo and MRC5 cells.
VZV perturbs TNF-!-induced NF-"B binding to a specific promoter in vivo.To go one step further into the mechanism by which VZV impairs ICAM-1 inducibility by TNF-#, ChIP assays were carried out with MeWo cells to compare the in vivo recruitment of p50, p65, and p52 to the icam-1 and il-8 promoters. Cells infected for 36 h were treated for 60 min with TNF-# (200 U/ml). After ChIP assays using specific antibodies against p50, p52, and p65, quantitative PCR
am-FIG. 6. VZV destabilizes p65-p50 heterodimers and increases their p100 association. (A) Total cell extracts from mock- and VZV-infected MeWo cells were incubated overnight with 2 &g of antibodies directed against p65, p50, and p100/p52. An antibody directed against hemagglutinin (HA) was used to control the specificity of the immunoprecipitation (IP). A Western blot (Wb) analysis was used to identify the complexes present in the cells. The results were quantified using Quantity One software from Bio-Rad. The mean value is presented under each band. The results were quantified by considering the mock-infected cell value as 1. (B) Nuclear extracts were made from mock- and VZV-infected MeWo cells treated with TNF-# for 1 h. p65 was then immunoprecipitated from these nuclear extracts, and Western blot analysis was used to identify the p65-associated subunits.
plification of a 100-bp region surrounding the proximal NF-"B site of the icam-1 promoter was carried out. Immu-noprecipitation using an irrelevant antibody (anti-Flag) as well as a PCR with primers amplifying a noncoding region downstream of the albumin gene was used as a specificity control (data not shown). As shown in Fig. 8A, TNF-# treatment induced p65 recruitment to the proximal NF-"B site of the icam-1 promoter in mock-infected cells, while it was not recruited in VZV-infected cells. The basal level of p65 at the promoter was not significantly increased by in-fection, despite the fact that, as shown above, the nuclear p65 level was increased in VZV-infected cells (Fig. 5A, panel 1). The level of p50 present at the promoter did not significantly increase after TNF-# treatment. The basal level of p50 on the icam-1 promoter was significantly lower in VZV-infected cells than in mock-infected cells. Finally,
nei-ther TNF-# treatment nor VZV infection significantly mod-ulated p52 recruitment to the icam-1 promoter (Fig. 8A, bottom panel).
Unlike the case for icam-1, there was still a slight recruit-ment of p65 to the il-8 promoter in VZV-infected cells after TNF-# treatment (Fig. 8B, top panel). In VZV-infected cells, p50 was not recruited to the il-8 promoter upon TNF-# treat-ment, and its level was even lower than that in mock-infected cells (Fig. 8B, middle panel). p52 recruitment also showed that it was removed from the il-8 promoter following TNF-# treat-ment or VZV infection (Fig. 8B, bottom panel). We could therefore postulate that despite the VZV-induced increased nuclear levels of several NF-"B subunits (p65, c-Rel, and p52), infection abrogates p50/p65 recruitment to the icam-1 pro-moter, thereby explaining the loss of response of this gene to TNF-#.
FIG. 7. VZV-infected fibroblasts also show inhibition of NF-"B nuclear translocation. (A) MRC5 cells infected with the VZV strain rOka for 24 and 36 h were treated with TNF-# (500 U/ml) for 24 h. Total cell lysates were harvested, and the level of ICAM-1 was analyzed by Western blotting. Actin was used as a loading control. (B) MRC5 cells were either mock or VZV infected for 36 h prior to treatment with TNF-# (200 U/ml) for increasing times. The nuclear extracts were incubated with a radiolabeled probe carrying the sequence of the icam-1 promoter proximal NF-"B site. (C) MRC5 cells were either mock or VZV infected for 36 h prior to treatment with TNF-# (200 U/ml) for increasing times. The nuclear and cytoplasmic levels of various NF-"B subunits (p65, p50, and p100/p52) were analyzed by Western blotting. The nuclear translocation of the different NF-"B subunits was quantified using Quantity One software from Bio-Rad, and the mean value is shown under each band. The results were quantified by considering the quantity of subunits present in mock-infected untreated cells as 1. The I"B# protein level was also evaluated in this cell line. Nuclear contamination was assessed with anti-p105, and actin was used as a loading control.
VZV does not inhibit icam-1 and il-8 promoter region acet-ylation.Histone acetylation and histone deacetylase (HDAC) removal are often correlated with increased chromatin acces-sibility at NF-"B-responsive promoters (27). Promoter avail-ability was evaluated by analyzing histone H3 acetylation on K9 and the presence of HDAC3 on the promoters of the icam-1 and il-8 genes in MeWo cells. As shown by ChIP analysis in Fig. 9, there was an increase in the acetylated histone H3 level at the icam-1 and il-8 promoters after TNF-# treatment in mock-infected cells. VZV alone induced an increased acetyla-tion of these promoters, which was further enhanced by TNF-# (Fig. 9A). The experiment was normalized by performing a ChIP assay using an anti-histone H3 antibody. By ChIP assay, the HDAC3 level was shown to be decreased at the icam-1 and
il-8 promoters after both TNF-# treatment and VZV infection,
which correlates with the increased acetylation (Fig. 9B). From these data, it can be concluded that VZV inhibited
NF-"B recruitment to the icam-1 promoter region and, to a lesser extent, to the il-8 promoter after TNF-# treatment. The inhibition was observed both in vitro and in vivo, although VZV did not inhibit promoter acetylation, which appeared to be enhanced.
DISCUSSION
In this work, it was demonstrated for the first time that VZV is able to inhibit the expression of ICAM-1 in response to proinflammatory cytokines in infected melanoma cells and fi-broblasts. ICAM-1 has a crucial role in different aspects of the immune response. Expressed on endothelial cells, ICAM-1 allows the migration of leukocytes to inflammation sites, while its expression on antigen-presenting cells gives costimulatory signals and plays a crucial role in CD8!T-cell activation (40).
ICAM-1 is poorly expressed in skin cells, but its expression
FIG. 8. VZV perturbs NF-"B binding induced by TNF-# on the targeted promoters in vivo. Mock- and VZV-infected MeWo cells were treated for 1 h with TNF-# (200 U/ml), and ChIP assays using p65, p50, or p52 antibody were carried out on total cell lysates. Real-time PCR amplification of a 100-bp fragment from the icam-1 (A) or il-8 (B) promoter encompassing the proximal NF-"B site was carried out. The results were normalized by performing PCR on the DNA input.*, statistically different (P ( 0.05);**, not statistically different (P ) 0.05).
level can be up-regulated by proinflammatory cytokines such as IFN-$ or TNF-#, as is the case in the periphery of VZV cutaneous lesions, where the viral load is low. On the other hand, in the center of the lesions, where cells support a high viral load, ICAM-1 is not up-regulated in response to proin-flammatory cytokines (45). These cutaneous sites bear a high level of viral replication (7). Diminishing immune surveillance at these sites might allow the virus to replicate more efficiently. The most interesting feature beyond the down-regulation of ICAM-1 expression is that this inhibition actually specifically targets NF-"B, a transcription factor having a central role in the activation pathways of several genes. Indeed, the NF-"B activation pathway was inhibited, while STAT-1 was normally activated at 36 h postinfection (Fig. 3).
While I"B# protein has been demonstrated to be stabilized at short times of infection in VZV-infected fibroblasts (30) and HEK293 cells (data not shown), we observed a decrease in I"B# protein level in both MeWo and MRC5 cells at late times of infection. I"B# protein has a short turnover time (between 30 and 180 min) (26), and since VZV decreased the basal level of i"b# mRNA, this probably led to the decreased I"B# pro-tein level observed in both melanoma cells and fibroblasts at late times of infection. Furthermore, VZV inhibited its TNF-#-induced resynthesis. The NF-"B subunits (p65, c-Rel, and p52) present in the nuclei of VZV-infected cells were shown to be unable to bind the studied promoters. Our results for fibro-blasts show that the nuclear translocation of p50 and, to a lesser extent, p65 is strongly decreased by VZV infection. Nev-ertheless, there is still a p65 nuclear translocation induced by infection, but it never reaches the level observed in mock-infected TNF-#-treated cells. Furthermore, despite the I"B#
decrease at late times of infection, p50 did not translocate into the nucleus upon TNF-# treatment, and this was observed in two different cell lines, i.e., MeWo and MRC5. The coimmu-noprecipitation assays performed with MeWo cells tended to show that VZV destabilizes p50 and thus reduces the occur-rence of p65-p50 heterodimers, leading to an accumulation of p65 in the nuclei of infected cells independently of p50. It has been shown by ChIP assay that the icam-1 promoter, in oppo-sition to the il-8 promoter, has less affinity for NF-"B dimers containing p50-independent p65 (51), explaining partly why the il-8 promoter seemed less affected by the inhibitory effect of the infection, with the promoters with the most affinity for p50-independent complexes being the least inhibited by VZV. Another observation that has to be highlighted is that VZV-induced nuclear NF-"B subunits did not bind a probe carrying the icam-1 promoter NF-"B sequence in vitro, while they still slightly bound the NF-"B sequence present in the HIV LTR promoter. This could be correlated with a higher affinity of the VZV-induced nuclear NF-"B subunits for the LTR sequence than for the icam-1 sequence. Furthermore, supershift assays were performed to identify the subunits binding to each of the probes used. Despite a slight presence of p52, it was shown that these two probes bound the same subunits in response to TNF-#, i.e., p50 and p65.
VZV also induced a strong nuclear accumulation of p52 in MeWo cells and, to a lesser extent, in MRC5 cells. This phe-nomenon has been described for other viruses, such as Ep-stein-Barr virus and human T-cell leukemia virus (9, 19, 44, 46), but never for an alphaherpesvirus. We have also reported for the first time an alphaherpesvirus-induced nuclear translo-cation of p100 in both melanoma cells and fibroblasts. Not
FIG. 9. VZV does not shut off the icam-1 and il-8 promoter regions. ChIP assay analysis was carried out on mock- and VZV-infected MeWo cells, using an antibody specific for the K9-acetylated form of histone H3, normalized using an anti-H3 ChIP assay (A), or an antibody specific for HDAC3 (B). The immunoprecipitated DNA was subjected to PCR analysis using primers amplifying the promoter region of either icam-1 or il-8.
much is known about the mechanisms leading to the nuclear localization of p100, but its processing in the nucleus is IKK# dependent (48). The nuclear accumulation of p100 could very well play a role in the inhibition of NF-"B binding to cellular promoters. Indeed, p100 is one of the multiple NF-"B inhibi-tors containing ankyrin motifs, along with the I"Bs and p105 (11, 16, 34). Furthermore, an increase in p100-associated p65 in VZV-infected MeWo total cell lysates was observed, and p100 also seemed to be more associated with p50 in total cell lysates, which could partly explain its cytoplasmic retention. Nevertheless, the coimmunoprecipitation of p100 with p65 in nuclear extracts of both mock- and VZV-infected cells was not feasible (data not shown). The mechanisms underlying the VZV-induced nuclear accumulation of p100, along with its possible consequences, are currently under investigation.
It was shown that VZV activates NF-"B in macrophages and HEK293 cells in a Toll-like receptor 2-dependent manner, leading to proinflammatory cytokine expression (57). In this work, the induction of TNF-# (data not shown), IL-6 (data not shown), and IL-8 mRNA expression in VZV-infected MeWo cells was shown. Nevertheless, IL-8 induction by the virus could not solely be explained by p65 recruitment to its pro-moter. Indeed, ChIP assay analysis showed that VZV did not increase p65 recruitment to this promoter.
Herpes simplex virus type 1, another alphaherpesvirus closely related to VZV, activates NF-"B via the IKK complex pathway and needs this activation to replicate properly (21, 47). It was recently shown that the NF-"B complex selectively activates the expression of viral genes, such as the ICP0 gene, and inhibits cellular ones. This inhibition is due to modifica-tions of the chromatin structure in infected cells (6). We showed that VZV-induced NF-"B inhibition was not due to chromatin modifications at the promoter region, since histone H3 was still acetylated and HDAC3-containing complexes were removed. Nevertheless, while the shutoff does not seem to be due to acetylation inhibition or mRNA destabilization, we demonstrated in another study that the VZV immediate-early protein IE63 was able to interact with the transcription initiation complex and inhibit several cellular genes (10, 18). Furthermore, it has been shown for other NF-"B-dependent genes that to fully respond to NF-"B, the promoter must be derepressed by removal of a repressor complex containing p50 homodimers from the promoter region (27). Therefore, we postulate that the lower level of p50 at the promoters in VZV-infected cells could mean that this complex was removed by the infection, whereas no transcriptionally active heterodimers were recruited. Moreover, we also observed an inhibition of NF-"B recruitment in vitro by mobility shift assay, suggesting that it is probably a direct modification of the NF-"B dimer that is responsible for the inhibition. Besides, in the case of herpes simplex virus type 1, NF-"B was needed for virus rep-lication, especially for ICP0 expression. The occurrence of functional NF-"B binding sites in the VZV genome has not been studied much, but it was recently shown that the inter-genic region between orf63 and orf62 contains a nonfunctional one (32). It would be worth studying the replication and viral gene expression of VZV in cells unable to activate both NF-"B pathways. Nuclear NF-"B could either have a direct effect on viral promoter stimulation or an indirect effect by activating cellular factors that promote or slow down viral replication.
Indeed, NF-"B is also involved in cell cycle progression, par-ticularly by stimulating cyclin D1 expression (for a review, see reference 33). Also, CDK1 has been shown to greatly influence the localization and repressor activity of the VZV protein IE63 (22), and the use of the CDK1 inhibitor roscovitine signifi-cantly slows down VZV replication in MeWo cells (53).
Taken together, these results show that VZV is able to inhibit NF-"B nuclear translocation by destabilizing p50. Be-cause p65-p50 heterodimers are crucial for TNF-# induction of the icam-1 gene, this could explain why this gene is no longer induced despite correct acetylation of the promoter (Fig. 10). Therefore, it seems that VZV modulates several aspects of the immune response by modulating NF-"B nuclear shuttling and its recruitment to cellular promoters. NF-"B plays a central role in innate and adaptive immune responses. Its activation during early stages of viral infection leads to the expression of several immune response genes, such as those for proinflam-matory cytokines (IFN-%, TNF-#, IL-6, and IL-8), chemokines (RANTES), and adhesion molecules (ICAM-1 and VCAM-1). NF-"B also strongly induces major histocompatibility complex class I and CD80/86 expression on antigen-presenting cells, thus increasing T-cell activation.
Regulating the actions of this transcription factor will lead to evident advantages for the control of infection progression, especially in melanocytes, which bear high viral replication loads in the skin.
ACKNOWLEDGMENTS
This work was supported by a grant from the National Fund for Scientific Research (FNRS, Brussels, Belgium).
N.E. is a Ph.D. student and teacher’s assistant at the University of Lie`ge, E.D. is a research associate at the FNRS, C.S.-D. is senior research associate at the University of Lie`ge, and J.P. is a research director at the FNRS.
FIG. 10. VZV inhibits icam-1 transcription upon TNF-# treatment by targeting p50-p65 heterodimers. VZV inhibits NF-"B recruitment to the icam-1 promoter region and, to a lesser extent, to the il-8 promoter after TNF-# treatment. Inhibition was observed both in vitro and in vivo, although VZV did not inhibit promoter acetylation but, on the contrary, enhanced it. VZV is able to inhibit NF-"B nuclear trans-location by destabilizing p50. p65-p50 heterodimers are crucial for TNF-# induction of the icam-1 gene, explaining why this gene is no longer induced.
REFERENCES
1. Abendroth, A., and A. Arvin. 2000. Host response to primary infection, p. 142–156. In A. Arvin and A. Gershon (ed.), Varicella-zoster virus: virology and clinical management. Cambridge University Press, Cambridge, United Kingdom.
2. Abendroth, A., I. Lin, B. Slobedman, H. Ploegh, and A. M. Arvin. 2001. Varicella-zoster virus retains major histocompatibility complex class I pro-teins in the Golgi compartment of infected cells. J. Virol. 75:4878–4888. 3. Abendroth, A., G. Morrow, A. L. Cunningham, and B. Slobedman. 2001.
Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host. J. Virol. 75:6183– 6192.
4. Abendroth, A., B. Slobedman, E. Lee, E. Mellins, M. Wallace, and A. M. Arvin.2000. Modulation of major histocompatibility class II protein expres-sion by varicella-zoster virus. J. Virol. 74:1900–1907.
5. Amici, C., G. Belardo, A. Rossi, and M. G. Santoro. 2001. Activation of I kappa B kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy. J. Biol. Chem. 276:28759–28766.
6. Amici, C., A. Rossi, A. Costanzo, S. Ciafre, B. Marinari, M. Balsamo, M. Levrero, and M. G. Santoro.2006. Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J. Biol. Chem. 281:7110–7117. 7. Arvin, A. M. 1996. Varicella-zoster virus. Clin. Microbiol. Rev. 9:361–381. 8. Beinke, S., and S. C. Ley. 2004. Functions of NF-kappaB1 and NF-kappaB2
in immune cell biology. Biochem. J. 382:393–409.
9. Beraud, C., S. C. Sun, P. Ganchi, D. W. Ballard, and W. C. Greene. 1994. Human T-cell leukemia virus type I Tax associates with and is negatively regulated by the NF-kappa B2 p100 gene product: implications for viral latency. Mol. Cell. Biol. 14:1374–1382.
10. Bontems, S., E. Di Valentin, L. Baudoux, B. Rentier, C. Sadzot-Delvaux, and J. Piette.2002. Phosphorylation of varicella-zoster virus IE63 protein by casein kinases influences its cellular localization and gene regulation activity. J. Biol. Chem. 277:21050–21060.
11. Brown, K., S. Park, T. Kanno, G. Franzoso, and U. Siebenlist. 1993. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc. Natl. Acad. Sci. USA 90:2532–2536.
12. Chen, J. J., Z. Zhu, A. A. Gershon, and M. D. Gershon. 2004. Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell 119:915–926. 13. Croen, K. D., J. M. Ostrove, L. J. Dragovic, and S. E. Straus. 1988. Patterns
of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc. Natl. Acad. Sci. USA 85:9773–9777.
14. Degitz, K., L. J. Li, and S. W. Caughman. 1991. Cloning and characterization of the 5'-transcriptional regulatory region of the human intercellular adhe-sion molecule 1 gene. J. Biol. Chem. 266:14024–14030.
15. Dejardin, E. 2006. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Phar-macol. 72:1161–1179.
16. Dejardin, E., G. Bonizzi, A. Bellahcene, V. Castronovo, M. P. Merville, and V. Bours.1995. Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells. Oncogene 11:1835–1841.
17. Diamond, M. S., D. E. Staunton, S. D. Marlin, and T. A. Springer. 1991. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 65:961–971.
18. Di Valentin, E., S. Bontems, L. Habran, O. Jolois, N. Markine-Goriaynoff, A. Vanderplasschen, C. Sadzot-Delvaux, and J. Piette.2005. Varicella-zoster virus IE63 protein represses the basal transcription machinery by disorga-nizing the pre-initiation complex. Biol. Chem. 386:255–267.
19. Eliopoulos, A. G., J. H. Caamano, J. Flavell, G. M. Reynolds, P. G. Murray, J. L. Poyet, and L. S. Young.2003. Epstein-Barr virus-encoded latent infec-tion membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway. Oncogene 22:7557–7569.
20. Gilden, D. H., Y. Rozenman, R. Murray, M. Devlin, and A. Vafai. 1987. Detection of varicella-zoster virus nucleic acid in neurons of normal human thoracic ganglia. Ann. Neurol. 22:377–380.
21. Gregory, D., D. Hargett, D. Holmes, E. Money, and S. L. Bachenheimer. 2004. Efficient replication by herpes simplex virus type 1 involves activation of the I"B kinase-I"B-p65 pathway. J. Virol. 78:13582–13590.
22. Habran, L., S. Bontems, E. Di Valentin, C. Sadzot-Delvaux, and J. Piette. 2005. Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity. J. Biol. Chem. 280:29135–29143.
23. Harson, R., and C. Grose. 1995. Egress of varicella-zoster virus from the melanoma cell: a tropism for the melanocyte. J. Virol. 69:4994–5010. 24. Hata, A., L. Zerboni, M. Sommer, A. A. Kaspar, C. Clayberger, A. M.
Krensky, and A. M. Arvin.2001. Granulysin blocks replication of
varicella-zoster virus and triggers apoptosis of infected cells. Viral Immunol. 14:125– 133.
25. Hayden, M. S., and S. Ghosh. 2004. Signaling to NF-kappaB. Genes Dev. 18:2195–2224.
26. Herrero, J. A., P. Mathew, and C. V. Paya. 1995. LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. J. Virol. 69:2168– 2174.
27. Hoberg, J. E., F. Yeung, and M. W. Mayo. 2004. SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and sur-vival. Mol. Cell 16:245–255.
28. Hou, J., V. Baichwal, and Z. Cao. 1994. Regulatory elements and transcrip-tion factors controlling basal and cytokine-induced expression of the gene encoding intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. USA 91:11641–11645.
29. Ito, M., T. Nakano, T. Kamiya, K. Kitamura, T. Ihara, H. Kamiya, and M. Sakurai.1991. Effects of tumor necrosis factor alpha on replication of vari-cella-zoster virus. Antivir. Res. 15:183–192.
30. Jones, J. O., and A. M. Arvin. 2006. Inhibition of the NF-"B pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. J. Virol. 80:5113–5124.
31. Jones, J. O., and A. M. Arvin. 2005. Viral and cellular gene transcription in fibroblasts infected with small plaque mutants of varicella-zoster virus. An-tivir. Res. 68:56–65.
32. Jones, J. O., M. Sommer, S. Stamatis, and A. M. Arvin. 2006. Mutational analysis of the varicella-zoster virus ORF62/63 intergenic region. J. Virol. 80:3116–3121.
33. Joyce, D., C. Albanese, J. Steer, M. Fu, B. Bouzahzah, and R. G. Pestell. 2001. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 12:73–90.
34. Kanno, T., G. Franzoso, and U. Siebenlist. 1994. Human T-cell leukemia virus type I Tax-protein-mediated activation of NF-kappa B from p100 (NF-kappa B2)-inhibited cytoplasmic reservoirs. Proc. Natl. Acad. Sci. USA 91:12634–12638.
35. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-"B activity. Annu. Rev. Immunol. 18:621–663. 36. Koropchak, C. M., S. M. Solem, P. S. Diaz, and A. M. Arvin. 1989.
Investi-gation of varicella-zoster virus infection of lymphocytes by in situ hybridiza-tion. J. Virol. 63:2392–2395.
37. Kouskouti, A., and I. Talianidis. 2005. Histone modifications defining active genes persist after transcriptional and mitotic inactivation. EMBO J. 24:347– 357.
38. Ku, C. C., L. Zerboni, H. Ito, B. S. Graham, M. Wallace, and A. M. Arvin. 2004. Varicella-zoster virus transfer to skin by T cells and modulation of viral replication by epidermal cell interferon-alpha. J. Exp. Med. 200:917–925. 39. Lebedeva, T., N. Anikeeva, S. A. Kalams, B. D. Walker, I. Gaidarov, J. H.
Keen, and Y. Sykulev.2004. Major histocompatibility complex class I-inter-cellular adhesion molecule-1 association on the surface of target cells: im-plications for antigen presentation to cytotoxic T lymphocytes. Immunology 113:460–471.
40. Lebedeva, T., M. L. Dustin, and Y. Sykulev. 2005. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr. Opin. Immunol. 17:251– 258.
41. Moffat, J. F., M. D. Stein, H. Kaneshima, and A. M. Arvin. 1995. Tropism of varicella-zoster virus for human CD4!and CD8!T lymphocytes and
epi-dermal cells in SCID-hu mice. J. Virol. 69:5236–5242.
42. Montag, C., J. Wagner, I. Gruska, and C. Hagemeier. 2006. Human cyto-megalovirus blocks tumor necrosis factor alpha- and interleukin-1%-medi-ated NF-"B signaling. J. Virol. 80:11686–11698.
43. Morrow, G., B. Slobedman, A. L. Cunningham, and A. Abendroth. 2003. Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J. Virol. 77:4950–4959.
44. Munoz, E., and A. Israel. 1995. Activation of NF-kappa B by the Tax protein of HTLV-1. Immunobiology 193:128–136.
45. Nikkels, A. F., C. Sadzot-Delvaux, and G. E. Pierard. 2004. Absence of intercellular adhesion molecule 1 expression in varicella zoster virus-infected keratinocytes during herpes zoster: another immune evasion strategy? Am. J. Dermatopathol. 26:27–32.
46. Paine, E., R. I. Scheinman, A. S. Baldwin, Jr., and N. Raab-Traub. 1995. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. J. Virol. 69:4572–4576. 47. Patel, A., J. Hanson, T. I. McLean, J. Olgiate, M. Hilton, W. E. Miller, and
S. L. Bachenheimer.1998. Herpes simplex type 1 induction of persistent NF-kappa B nuclear translocation increases the efficiency of virus replica-tion. Virology 247:212–222.
48. Qing, G., and G. Xiao. 2005. Essential role of IkappaB kinase alpha in the constitutive processing of NF-kappaB2 p100. J. Biol. Chem. 280:9765–9768. 49. Rothlein, R., M. Czajkowski, M. M. O’Neill, S. D. Marlin, E. Mainolfi, and V. J. Merluzzi.1988. Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. J. Immunol. 141:1665– 1669.
Varicella-zoster virus latency in the adult rat is a useful model for human latent infection. Neurology 45:S18–S20.
51. Sasaki, C. Y., T. J. Barberi, P. Ghosh, and D. L. Longo. 2005. Phosphory-lation of RelA/p65 on serine 536 defines an I"B#-independent NF-"B path-way. J. Biol. Chem. 280:34538–34547.
52. Staunton, D. E., S. D. Marlin, C. Stratowa, M. L. Dustin, and T. A. Springer. 1988. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 52:925–933.
53. Taylor, S. L., P. R. Kinchington, A. Brooks, and J. F. Moffat. 2004. Rosco-vitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus. J. Virol. 78:2853–2862.
54. Torigo, S., T. Ihara, and H. Kamiya. 2000. IL-12, IFN-gamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella. Microbiol. Immunol. 44:1027–1031. 55. Volanti, C., J. Y. Matroule, and J. Piette. 2002. Involvement of oxidative
stress in NF-kappaB activation in endothelial cells treated by photodynamic therapy. Photochem. Photobiol. 75:36–45.
56. Voraberger, G., R. Schafer, and C. Stratowa. 1991. Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5'-regulatory region. Induction by cytokines and phorbol ester. J. Immunol. 147:2777– 2786.
57. Wang, J. P., E. A. Kurt-Jones, O. S. Shin, M. D. Manchak, M. J. Levin, and R. W. Finberg.2005. Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J. Virol. 79:12658–12666.
58. Weller, T. H., and H. M. Witton. 1958. The etiologic agents of varicella and herpes zoster; serologic studies with the viruses as propagated in vitro. J. Exp. Med. 108:869–890.
59. Zerboni, L., M. Sommer, C. F. Ware, and A. M. Arvin. 2000. Varicella-zoster virus infection of a human CD4-positive T-cell line. Virology 270:278–285.
